Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab and Chemoradiotherapy in High-risk pMMR/MSS Locally Advanced Rectal Cancer
NCT07527520Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Jun 2026
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of serplulimab in rectal cancer (3 arms), sponsored by Fudan University. Primary endpoint: Complete Remission Rate at 1 year. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
serplulimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT07527520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07527520.